Induction of apoptosis by synergistic inhibition of noscapine and taxol on PC-3 human prostate cancer ceil line

Rabzia, A.; Khazaei, M.; Rasbidi, Z.
June 2014
Iranian Journal of Reproductive Medicine;Jun2014 Supplement, Vol. 12, p98
Academic Journal
Introduction: Prostate cancer is a leading cause of cancer related death in most developed countries. Combination treatment with multiple therapeutic agents has been used to enhance the efficacy of treatment in controlling cancer cells. In the present study, the apoptotic effects of taxol (chemotherapy agent) and noscapine opium antitussive) on human prostate cancer cell line (PC-3) has been investigated. Materials and Methods: PC-3 cells were treated with taxol (50 nM), noscopine (50 uM) and their combination for 48 hours. Untreated cells were used as control. Treatments-induced apoptosis was assessed by AO/EB (acridine orange/ ethidium bromide) double staining assay. The mRNA expression of pro-apototic Box and anti-apoptotic Bcl-2 was determined by Relative RT-PCR (reverse transcription polymerase chain reaction). Data was analyzed by one way ANOVA. Results: PC-3 cells undergoing apoptosis following treatment with taxol (50 nM), noscapine (50 uM) and their combination compared to untreated cells after 48 hours. The combination group induced highest increase in cell apoptotic. Noscapine or taxol and their combination treatments decreased mRNA expression of anti-apoptotic molecule Bcl-2 and increased mRNA expression of pro-apoptotic molecule Box and Bax to Bcl-2 ratio. Conclusion: The present in vitro study indicates that noscapine and taxol combination treatment is effective against PC-3 cells by induction of apoptosis. Therefore, it may provide a novel therapeutic strategy to improve the treatment efficiency of prostate cancer therapy.


Related Articles

  • Clues for a Prostate Cancer Decision. Spake, Amanda; Brink, Susan // U.S. News & World Report;5/23/2005, Vol. 138 Issue 19, p63 

    Focuses on how the diagnosis of prostate cancer is riddled with uncertainty. How to weigh the benefits of treatment including chemotherapy.

  • Combo Tx in high-risk Ca may reshape paradigm. Guttman, Cheryl // Urology Times;Aug2007, Vol. 35 Issue 10, p1 

    The article reports on the findings of American Urological Association (AUA) studies on localized prostate cancer management. The study focused on several cancer management measures, such as chemotherapy and cryoablation. The study found the effectiveness in docetaxel chemotherapy, although...

  • An update on chemotherapy for hormone-refractory prostate cancer. Cooney, Kathleen A.; Smith, David C.; Pienta, Kenneth J. // Contemporary Urology;Apr2000, Vol. 12 Issue 4, p33 

    Provides information on the chemotherapy for hormone-refractory prostate cancer. Details on hormone withdrawal responses; Discussion on androgen ablation during chemotherapy; Estramustine-based chemotherapy regimens.

  • Liarozole may offer improved control for some refractory-PCa patients. Overmyer, Mac // Urology Times;Jun97, Vol. 25 Issue 6, p39 

    Compares the efficacy of the drug liarozole fumarate with cyproterone acetate in terms of survival among patients with advanced prostate cancer. Improvement of pain threshold; Decrease in prostate screening antigen (PSA) response; Background on liarozole; Survival rate; Side effects.

  • PCa therapy post-chemo should be directed to bone. Dosa, Laszlo // Urology Times;Oct2002, Vol. 30 Issue 10, p18 

    Discusses results of a study examining the patterns of cancer relapse in hormone-refractory prostate cancer patients. Primary site of relapse in patients who had progression in both bone and soft-tissue disease; Development of chemotherapy strategies directed to the bone.

  • Rapid progression of prostate cancer in men with a BRCA2 mutation. Narod, S A; Neuhausen, S; Vichodez, G; Armel, S; Lynch, H T; Ghadirian, P; Cummings, S; Olopade, O; Stoppa-Lyonnet, D; Couch, F; Wagner, T; Warner, E; Foulkes, W D; Saal, H; Weitzel, J; Tulman, A; Poll, A; Nam, R; Sun, P; Hereditary Breast Cancer Study Group // British Journal of Cancer;7/22/2008, Vol. 99 Issue 2, p371 

    Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and...

  • New indication for prostate cancer therapy.  // Drug Topics;7/8/96, Vol. 140 Issue 13, p7 

    Reports that Eulexin (flutamide, Schering-Plough) has received an expanded indication for the treatment of locally confined stage B2-C carcinoma of the prostate.

  • Refractory disease, new horizons and patient–physician relationships. Glode, L M; Petrylak, D P // Prostate Cancer & Prostatic Diseases;1999 Supplement 1, Vol. 2 Issue 1, p19 

    Understanding the role of chemotherapy for prostate cancer has advanced along two axes, better definition of endpoints, and biologic understanding of disease targets. Use of PSA as a surrogate endpoint makes possible the more rational design of phase III trials which will include survival and...

  • Treatment Options in Hormone-Refractory Prostate Cancer: Current and Future Approaches. Harris, K.A.; Reese, D.M. // Drugs;Dec2001, Vol. 61 Issue 15, p2177 

    Prostate cancer is the second leading cause of cancer mortality among men in Western countries. The initial treatment of advanced prostate cancer is suppression of testicular androgen production by medical or surgical castration, but nearly all men with metastases will develop disease...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics